Will ‘Vemlidy’ become a new power in chronic hepatitis B treatment market?

Pharmaceutical companies have been highly competitive to develop new chronic hepatitis B treatments. In the competition, Gilead developed a new drug called ‘Vemlidy(generic name: tenofovir alafenamide, aka. TAF)’ and acquired approvals last November from the FDA and on the 16^th in Korea.

This is not the first time that Gilead showed its passion to development of hepatitis B treatments. This is...